Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally +6 more
wiley +1 more source
Medication Adherence Behavior Assessed Using a Digital Bottle Cap: Retrospective Cohort Study. [PDF]
Nowojewski A +14 more
europepmc +1 more source
Power priors for latent variable mediation models under small sample sizes
Abstract Latent variable models typically require large sample sizes for acceptable efficiency and reliable convergence. Appropriate informative priors are often required for gainfully employing Bayesian analysis with small samples. Power priors are informative priors built on historical data, weighted to account for non‐exchangeability with the ...
Lihan Chen +2 more
wiley +1 more source
Dissolution-permeation approach for biopharmaceutical evaluation: a feasibility study using naproxen. [PDF]
Sitovs A +3 more
europepmc +1 more source
Biopharmaceutical Profiling of Herpetrione: A BCS II Properties and P-gp Substrate Guiding Nanoparticle Design. [PDF]
Wang F +5 more
europepmc +1 more source
Accurate prediction of asparagine deamidation in biologics using advanced machine learning models. [PDF]
Ahmed S +7 more
europepmc +1 more source
Pharmacokinetic and Biopharmaceutic Terminology [PDF]
openaire +2 more sources
Olfactory tuft cells communicate with other mucosal cells in maintaining olfactory epithelial immunity and sensory function. Disruption of tuft cell signalling pathways causes a skewed immune response, leading to heightened inflammation and increased activation of the quiescent stem cells, which are further exacerbated by viral infection.
Sai‐Sai Zhang +7 more
wiley +1 more source
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical <i>EGFR</i> Mutations: A Phase Ib Study. [PDF]
Zhou H +15 more
europepmc +1 more source

